Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

properties of the s-EH inhibitors to the stage where we could present a convincing picture to venture groups of compounds ready to move to the clinic."

In 2005, the company raised more than $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures.

Today, the biotech company, based in Hayward, is dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders, Hammock said. It is billed as the "world's leading company focused on s-EH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology."

"Our main goal," Hammock said, "was to set up a system of a science-driven company where we reduce the cost of drug registration by using very good incisive science. We also want to reward and motivate the people who do the work; provide a funding and training environment to help teach students and postgraduates to write proposals; and allow scientists to move between an academic and industrial environment in the early stage to help determine career directions."

Another goal: a low-cost, affordable drug. "The sickest people in the world, of course, cannot pay for the drugs they need," Hammock said. "The chemistry developed around the s-EH inhibitors allows us to make powerful but inexpensive drugs that could be produced in developing countries."

Meanwhile, the clinical trials under way represent two firsts, said James Sabry, president and chief executive officer of Arte Therapeutics. "This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension."

."AR9281 has demonstrated an excellent
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of ... report to their offering. This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... Research Institute (NHGRI), one of the National Institutes ... Sequencing Research Network will begin sequencing 12 more ... and several important insects, as part of its ... genome. , The National Advisory Council for Human ...
... a marvel of versatility, creating a variety of cells that ... out these tasks, immune cells follow a career path that ... in the May 2005 issue of Immunity, Fox Chase Cancer ... Dietmar J. Kappes, Ph.D., show that cell-receptor signaling strength influences ...
... the biological literature resides in full text articles, instead ... publicly available literature data mining tools. Most literature mining ... extracted from curated gene or protein databases. This is ... the many name variants which are used to refer ...
Cached Biology News:NHGRI targets 12 more organisms for genome sequencing 2NHGRI targets 12 more organisms for genome sequencing 3NHGRI targets 12 more organisms for genome sequencing 4NHGRI targets 12 more organisms for genome sequencing 5Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3
(Date:4/25/2015)... Join us for a webinar at 12 pm ... using the Transcreener® ADP Assay , Register Now ... being incorporated into lead development efforts because longer engagement ... therapeutic window and reduced side effects. Though residence ... surface plasmon resonance, conjugation of drugs can affect their ...
(Date:4/24/2015)... , April 24, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... MaterialScience as the supplier of bio-succinic acid used ... polyurethanes for textile applications that Bayer MaterialScience has ... launched IMPRANIL ® eco, a series of ... reaches as high as 65%.  IMPRANIL ® ...
(Date:4/24/2015)... 24, 2015 Seoul Semiconductor announced ... various applications in the lighting market. In ... of this technology in emerging markets such as ... wide range of applications such as streetlight and ... lighting. , First launched in 2005 the Acrich ...
(Date:4/23/2015)... , April 23, 2015 BioTE Medical President ... book "Age Healthier Live Happier - Avoiding Over-Medication through ... Age Management Medicine Group Conference at JW Marriott / ... ",Age Healthier Live Happier, is a welcomed ... over-medication and searching for a higher quality of life ...
Breaking Biology Technology:BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3
... Cylene Pharmaceuticals today announced,the initiation of a Phase ... carcinoid/neuroendocrine tumors (C/NET), which are malignant,cancers arising from ... "Quarfloxin (CX-3543) is a small molecule ... abnormal nucleoli of cancer cells, thereby,selectively inducing apoptotic ...
... PAREXEL International,Corporation (Nasdaq: PRXL ), ... the Company has been named the "Best Contract,Research ... award was,presented to PAREXEL at the fourth annual ... London, England. The Scrip Awards are designed to,celebrate ...
... Precision(R), Inc. a,leading provider of imaging, measurement, and ... that it will introduce a new imaging,system at ... conference with,twice the resolution of traditional microscopes. ... system developed by scientists at the, University of ...
Cached Biology Technology:Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 2Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 3PAREXEL Receives Best CRO Award from Scrip 2PAREXEL Receives Best CRO Award from Scrip 3PAREXEL Receives Best CRO Award from Scrip 4Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes 2
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... yellow solid. An N-nitroso-containing diabetogenic compound ... donor in pancreatic islets. An antibiotic ... alkylation and DNA strand breaks in ... HPLC. Soluble in H 2 O. ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: